277 материалов по теме, собраны автоматически из проверенных источников
Phase III TAISHAN-302 Trial Shows Tam-Peli Significantly Improves Survival in Relapsed Small-Cell Lung Cancer Yahoo Finance
Phase III TAISHAN-302 Trial Shows Tam-Peli Significantly Improves Survival in Relapsed Small-Cell Lung Cancer PR Newswire
Phase III ARTEMIS-008 Trial Shows Risvutatug Rezetecan Significantly Improves Overall Survival in Relapsed Small-Cell Lung Cancer PR Newswire
Tam-Peli meets primary endpoint for relapsed small-cell lung cancer in phase III trial The Clinical Trial Vanguard
Phase III TAISHAN-302 trial shows Tam-Peli significantly improves survival in relapsed small-cell lung cancer EurekAlert!
Antibody-Drug Combination Falls Short in First-Line PD-L1-High Metastatic Lung Cancer Trial Bioengineer.org
Phase III ARTEMIS-008 trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer EurekAlert!
Results from the international phase 3 SWOG S1827 MAVERICK trial show that brain MRI surveillance alone improved cognitive failure-free survival compared with MRI surveillance plus prophylactic cranial irradiation (PCI) in patients with small-cell lung cancer (SCLC). The findings support MRI surveillance alone as the…
Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to a prespecified interim analysis of the phase 3 HARMONi-2 trial presented today at the IASLC 2026 World Conference on Lung…
Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or after platinum-based…
Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS) of 50% or greater…
The phase 3 TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC). The findings were…
Merck, Gilead’s failed Trodelvy lung cancer trial shows better China results fiercepharma.com
Bispecific Antibody Meets Antibody-Drug Conjugate in Promising Small Cell Lung Cancer Trial Bioengineer.org
Специалисты больницы Бах Май указывают на 4 фактора, вызывающих рак легких даже без курения. Vietnam.vn